1 / 6

Fragment-based Drug Discovery Market Expected to Reach USD 1.2 Billion Globally in 2023

Fragment-based Drug Discovery Market Expected to Reach USD 1.2 Billion Globally in 2023Fragment-based drug discovery has been recognized as a potential method to design novel molecules as this technique discovery utilizes comparatively small libraries of ‘fragments or ligands’ that are of low-molecular weights. Factors such as less time-consumption and easy access to biophysical fragment screening techniques are driving the growth of the global fragment-based drug discovery market. Know more http://goo.gl/jR0Jfz

priyap01
Download Presentation

Fragment-based Drug Discovery Market Expected to Reach USD 1.2 Billion Globally in 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Transparency Market Research Fragment-based Drug Discovery Market Expected to Reach USD 1.2 Billion Globally in 2023 Published Date 14-Oct-2015 111 Page Report Request Sample Buy Now Press Release http://www.transparencymarketresearch.com/pressrelease/fragment-based-drug-discovery- market.htm Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com

  2. Radiopharmaceuticals Market REPORT DESCRIPTION Fragment-based Drug Discovery Market Expected to Reach USD 1.2 Billion Globally in 2023 The assurance of logical and efficient lead innovation has fuelled interest for fragment-based drug discovery (FBDD). This enthusiasm is further complemented by a paradigm shift from conventional techniques like high-throughput screening (HTS) towards design intensive approaches, enabled by computational and structural biology. Fragment-based drug discovery utilizes comparatively small libraries of “fragments or ligands” that are of low-molecular weights. These fragments are evaluated for binding affinity, then incrementally altered into more potent molecules against the biological target(s) of interest. The major advantages of this technique that are expected to drive the popularity of FBDD among pharmaceutical companies are less cost and time process, streamlined equipment operability, and higher success rates of hits. Major factors likely to boost the growth of the market are Simpler and less time consuming technique, streamlining and easy access to advanced biophysical techniques could drive the market in the near future. However, lower level of potency in few of the compounds derived from fragment screening and requirement of high protein and unique fragment library to conduct studies would hamper the growth of the fragment-based drug discovery market during the forecast period. Browse Full Report with TOC: http://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html Fragment screening services and fragment optimization collectively form the fragment-based drug discovery market. Fragment screening segment was further segmented into biophysical services and non-biophysical services. Biophysical services are further segmented into techniques such as Nuclear Magnetic Resonance (NMR) Spectroscopy, Differential scanning Fluorimetry (DSF) Assay (Thermal Shift), Fluorescence Polarization (FP), Isothermal Titration Calorimetry (ITC), X-ray Crystallography, Surface Plasmon Resonance, Biolayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, and others (biochemical assays). NMR was the largest segment of the FBDD market, accounting for approximately 19.7% share in 2014. The technique is expected to maintain its leadership position during the forecast period. Advantages of NMR such as high reliability, easy operability, and wide versatility are likely to fuel the growth of the NMR segment. However, high procurement cost and availability of cheaper alternatives could hamper market growth. 2 Transparency Market Research

  3. Radiopharmaceuticals Market Demand for fragment-based drug discovery is increasing in pharmaceutical companies, CROs, and academic & research institutions as these procedures detect fragments with low affinity binding which is generally difficult to detect by most other methods. Based on end-users the FBDD market has been segmented into biopharmaceutical companies, CROs, and academic and research institutions. Among these, biopharmaceutical companies emerged as the major FBDD service user, accounting for 46.0% in 2014. Low productivity, dwindling pipeline, and rising R&D costs are inducing biopharmaceutical companies to narrow down the gaps in the current drug discovery processes, thereby boosting productivity and implementation of FBDD as drug discovery technique. Enquiry Before Buying: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741 Geographically, the fragment based drug discovery market has been segmented into North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America has been further segmented into the U.S. and Canada; Europe into Germany, the U.K. and Rest of Europe; Asia Pacific into Australia, Japan, and Rest of Asia Pacific, Latin America into Brazil and Rest of Latin America, and rest of the world. The market revenue of fragment based drug discovery services for each geographical region for 2014 and 2023 along with forecast from 2015 to 2023 in respective regions in terms of USD million, has been explained in the geography section of the report. Browse Full Press Release @ http://www.transparencymarketresearch.com/pressrelease/fragment-based-drug-discovery-market.htm TABLE OF CONTENT Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Research Methodology: Assumptions Chapter 2 Executive Summary 2.1 Global Fragment-based Drug Discovery Market, Estimates and Forecast, By Revenue, 2013–2023 (US$ Mn) 2.2 Global Fragment-based Drug Discovery Market Revenue, by Services, 2014 (US$ Mn) 2.3 Global Fragment-based Drug Discovery Market Revenue, by End-user, 2014 (US$ Mn) 3 Transparency Market Research

  4. Radiopharmaceuticals Market 2.4 Global Market Share, by Geography, 2014 and 2023 (Value %) 2.5 Fragment-based Drug Discovery Market Snapshot Chapter 3 Fragment-based Drug Discovery Market Overview 3.1 Introduction 3.1.1 Hit to Lead 3.1.2 Progression to Candidates from Fragment Leads 3.2 Event Impact Analysis 3.3 Future Trends and Developments 3.4 Market Drivers 3.4.1 Simpler and less time consuming technique 3.4.2 Streamlining and easy access to advanced biophysical techniques 3.5 Restraints 3.5.1 Lower level of potency in few of the compounds derived from fragment screening 3.5.2 Requirement of high protein and unique fragment library for conducting studies 3.6 Opportunities 3.6.1 Merging of computational biology with biophysical techniques 3.6.2 Emerging economies to offer sustained growth opportunities 3.7 Porter’s Five Forces Analysis 3.8 Recent Developments in Fragment-based Drug Discovery 3.9 Fragment-based Drug Discovery: Case Histories 3.10 Market Share – Fragment-based Drug Discovery Market (2014) (%) 3.11 Market Attractiveness Analysis – Fragment-based Drug Discovery Market Chapter 4 Market Segmentation – By Services Component 4.1 Introduction 4.2 Comparative Analysis of FBDD and HTS 4.3 Global Fragment Screening Market Revenue for FBDD, 2013 – 2023 (US$ Mn) 4.3.1 Global Biophysical Techniques Market for FBDD (US$ Mn), 2013 – 2023) 4.3.1.1 Global NMR Spectroscopy Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.2 Global DSF Assay Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.3 Global Fluorescence Polarization (FP) Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.4 Global Isothermal Titration Calorimetry (ITC) Market Revenue for FBDD, 2013–2023 (US$ Mn) 4 Transparency Market Research

  5. Radiopharmaceuticals Market 4.3.1.5 Global X-ray Crystallography Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.6 Global SPR Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.7 Global Biolayer Interferometry Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.8 Global Mass Spectrometry (MS) Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.9 Global Capillary Electrophoresis (CE) Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.1.10 Global Other (Biochemical Assays) Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.3.2 Global Non-biophysical Techniques Market Revenue for FBDD, 2013–2023 (US$ Mn) 4.4 Global Fragment Optimization Market Revenue for FBDD, 2013–2023 (US$ Mn) Chapter 5 Market Segmentation – By End-user 5.1 Introduction 5.2 Global Market for Fragment-based Drug Discovery in Biopharmaceutical Companies, 2013–2023 (US$ Mn) 5.3 Global Market for Fragment-based Drug Discovery in CROs, 2013–2023 (US$ Mn) 5.4 Global Market for Fragment-based Drug Discovery in Academic and Research Institutions, 2013–2023 (US$ Mn) Chapter 6 Fragment-based Drug Discovery Market - Regional Analysis 6.1 Global Overview 6.2 North America Fragment-based Drug Discovery Market Overview 6.2.1 U.S. Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 6.2.2 Canada Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 6.3 Europe Fragment-based Drug Discovery Market Overview 6.3.1 Germany Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 6.3.2 U.K. Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 6.3.3 Rest of Europe Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 6.4 Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 6.4.1 Japan Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 6.4.2 Australia Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 6.4.3 Rest of Asia Pacific Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 6.5 LATAM Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 6.5.1 Brazil Fragment-based Drug Discovery Market Revenue, 2013 - 2023, (US$ Mn) 6.5.2 Rest of LATAM Fragment-based Drug Discovery Market Revenue, 2013 – 2023, (US$ Mn) 6.6 RoW Fragment-based Drug Discovery Market Revenue, 2013–2023 (US$ Mn) 5 Transparency Market Research

  6. Radiopharmaceuticals Market About Us Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ 6 Transparency Market Research

More Related